1. SERUM GLP-2 is Increased in Association with Excess Gestational Weight Gain.
- Author
-
Kahr, Maike K., Antony, Kathleen M., Galindo, Megan, Whitham, Megan, Hu, Min, Aagaard, Kjersti M., and Suter, Melissa A.
- Subjects
- *
OBESITY complications , *DIABETES complications , *INTESTINAL physiology , *WEIGHT gain in pregnancy , *BIOMARKERS , *ENDOTOXEMIA , *LIPOPOLYSACCHARIDES , *INTERLEUKINS , *MOTHERS , *TISSUE banks , *IMMUNOGLOBULINS , *INFLAMMATION , *BLOOD collection , *ENZYME-linked immunosorbent assay , *TUMOR necrosis factors , *DESCRIPTIVE statistics , *RESEARCH funding , *BODY mass index , *PEPTIDES , *LONGITUDINAL method , *PREGNANCY - Abstract
Objective Obesity in pregnancy bears unique maternal and fetal risks. Obesity has also been associated with chronic inflammation, including elevated serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Higher serum lipopolysaccharide (LPS) levels have been implicated in driving this inflammation, a phenomenon called metabolic endotoxemia (ME). GLP-2, a proglucagon-derived peptide, is believed to be integral in maintaining the integrity of the intestine in the face of LPS-mediated endotoxemia. We hypothesized that obesity and/or excess weight gain in pregnancy would be associated with an increase in maternal and neonatal markers of ME, as well as GLP-2. Study Design Paired maternal and neonatal (cord blood) serum samples (n = 159) were obtained from our pregnancy biobank repository. Serum levels of LPS, endotoxin core antibody-immunoglobulin M (EndoCAb-IgM), and GLP-2 were measured by ELISA. IL-6 and TNF-α were measured using a Milliplex assay. Results were stratified by maternal body mass index (BMI), maternal diabetes, and gestational weight gain (GWG). Results Maternal IL-6 is significantly decreased in the obese, diabetic cohort compared with the nonobese, nondiabetic cohorts (95.28 vs. 99.48 pg/mL, p = 0.047), whereas GLP-2 is significantly increased (1.92 vs. 2.89 ng/mL, p = 0.026). Neonatal TNF-α is significantly decreased in the obese cohort compared with the nonobese cohort (12.43 vs. 13.93 pg/mL, p = 0.044). Maternal GLP-2 is significantly increased in women with excess GWG compared with those with normal GWG (2.27 vs. 1.48 ng/mL, p = 0.014). We further found that neonatal IL-6 and TNF-α are negatively correlated with maternal BMI (–0.186, p = 0.036 and –0.179, p = 0.044, respectively) and that maternal and neonatal IL-6 showed a positive correlation (0.348, p < 0.001). Conclusion Although we observed altered levels of markers of inflammation (IL-6 and TNF-α) with maternal obesity and diabetes, no changes in LPS or endoCAb-IgM were observed. We hypothesize that the increased GLP-2 levels in maternal serum in association with excess GWG may protect against ME in pregnancy. Key Points Maternal serum levels of GLP-2, a proglucagon-derived peptide, are increased in obese, diabetic gravidae. Maternal serum GLP-2 levels are also increased in association with excess gestational weight gain compared with normal gestational weight gain. GLP-2 may be increased in association with obesity and weight gain to protect against metabolic endotoxemia in pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF